» Articles » PMID: 16793547

The E3 SUMO Ligase PIASy is a Regulator of Cellular Senescence and Apoptosis

Overview
Journal Mol Cell
Publisher Cell Press
Specialty Cell Biology
Date 2006 Jun 24
PMID 16793547
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Cellular senescence and apoptosis have evolved to restrain unwarranted proliferation of potentially tumorigenic cells. Here we show that overexpression of the E3 SUMO ligase PIASy in normal human fibroblasts recruits the p53 and Rb tumor suppressor pathways to provoke a senescence arrest. By contrast, in Rb-deficient fibroblasts, expression of PIASy leads to p53-dependent apoptosis. Induction of senescence requires PIASy E3 activity and is specific for this member of the PIAS ligase family. PIASy stimulates sumoylation and transcriptional activity of p53 and increases Rb-dependent corepression through recruitment to E2F-responsive promoters. Viral oncoprotein E6 suppresses both PIASy-induced senescence and sumoylation of PIASy substrates. Finally, we show that fibroblasts lacking PIASy exhibit a highly reduced propensity to undergo senescence in response to a prosenescence stimulus. Altogether, these data provide the first evidence for a direct role of an E3 SUMO ligase, and by implication of the SUMO pathway, in cellular senescence and apoptosis.

Citing Articles

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.

Shen J, Wang Q, Mao Y, Gao W, Duan S MedComm (2020). 2023; 4(3):e288.

PMID: 37256211 PMC: 10225743. DOI: 10.1002/mco2.288.


The Four Homeostasis Knights: In Balance upon Post-Translational Modifications.

Pieroni S, Castelli M, Piobbico D, Ferracchiato S, Scopetti D, Di-Iacovo N Int J Mol Sci. 2022; 23(22).

PMID: 36430960 PMC: 9696182. DOI: 10.3390/ijms232214480.


Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases.

Lara-Urena N, Jafari V, Garcia-Dominguez M Int J Mol Sci. 2022; 23(14).

PMID: 35887358 PMC: 9316396. DOI: 10.3390/ijms23148012.


Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review).

Wang L, Qian J, Yang Y, Gu C Int J Oncol. 2021; 59(3).

PMID: 34368858 PMC: 8360622. DOI: 10.3892/ijo.2021.5253.


SUMOylation modification-mediated cell death.

Sheng Z, Zhu J, Deng Y, Gao S, Liang S Open Biol. 2021; 11(7):210050.

PMID: 34255975 PMC: 8277462. DOI: 10.1098/rsob.210050.